Press release
Hypertension Pipeline Assessment - Clinical trials, FDA, EMA, and PMDA Approvals, Emerging Therapies, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight
Hypertension Pipeline
Hypertension (HTN) is systolic blood pressure (SBP) values of 130mmHg or more and/or diastolic blood pressure (DBP) more than 80 mmHg. Hypertension ranks among the most common chronic medical conditions characterized by a persistent elevation in the arterial pressure.
Hypertension has been among the most studied topics of the previous century and has been one of the most significant comorbidities contributing to the development of stroke, myocardial infarction, heart failure, and renal failure.
"Hypertension Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertension Market.
The Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Click here to know more about Hypertension Pipeline Insight Report offering: https://www.delveinsight.com/report-store/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's Hypertension Report covers around 100+ products under different phases of clinical development like
• Late-stage Hypertension products (Phase III)
• Mid-stage Hypertension products (Phase II)
• Early-stage Hypertension product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Hypertension Route of Administration
Emerging Hypertension Drugs Under Different Phases of Clinical Development Include:
• Firibastat: Quantum Genomics
• Baxdrostat (CIN-107): CinCor Pharma
• MLS-101: Minerals Therapeutics
• Zilebesiran (ALN-AGT): Alnylam Therapeutics
• IONIS-AGT-LRx:Ionis Pharmaceuticals
And Others
Further Hypertension product details are provided in the report. Download the Hypertension pipeline report to learn more about the emerging Hypertension therapies at: https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hypertension Pipeline Analysis
The Hypertension report provides insights into:
• The report provides detailed insights about companies that are developing therapies for the treatment of Hypertension with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Hypertension Treatment.
• Hypertension companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hypertension market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF Report for Hypertension pipeline assessment @ https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key companies in the Hypertension Therapeutics Market:
Some of the Hypertension companies working in the market are Quantum Genomics, CinCor Pharma, Minerals Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision,Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc.,Shanghai Pharmaceuticals Holding Co.Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma,LLC, pH Pharma, Nicox Ophthalmics,Inc., Ocular Therapeutix,Inc., Santen SAS, Whitecap Biosciences,LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co..Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IIDong Pharmaceutical Co Ltd, Qlaris Bio Inc and others.
Request for Sample PDF Report to know more about the Hypertension clinical trials - https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Hypertension Current Treatment Patterns
4. Hypertension - DelveInsight's Analytical Perspective
5. Hypertension Therapeutic Assessment
6. Hypertension Late Stage Products (Phase-III)
7. .Hypertension Mid-Stage Products (Phase-II)
8. .Hypertension Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Hypertension Products
11. Dormant Hypertension Products
12. Hypertension Discontinued Products
13. Hypertension Product Profiles
14. Key Companies in the Hypertension Market
15. Key Products in the Hypertension Therapeutics Segment
16. Dormant and Discontinued Products
17. Hypertension Unmet Needs
18. Hypertension Future Perspectives
19. Hypertension Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Hypertension drugs and therapies- https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Hpv-Induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Advanced Hepatocellular Carcinoma With Cpb Liver Cirrhosis Market: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Bone Grafts And Substitutes Market: https://www.delveinsight.com/report-store/bone-grafts-and-substitutes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Age Related Vision Dysfunction Market: https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Acute Pharyngitis Market: https://www.delveinsight.com/report-store/acute-pharyngitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertension Pipeline Assessment - Clinical trials, FDA, EMA, and PMDA Approvals, Emerging Therapies, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight here
News-ID: 2764506 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Hypertension
Hypertension Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hypertension Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hypertension Pipeline Report
• DelveInsight's Hypertension…
Hypertension Drugs Market - Breaking the Pressure: Hypertension Drugs Redefining …
Newark, New Castle, USA: The "Hypertension Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hypertension Drugs Market: https://www.growthplusreports.com/report/hypertension-drugs-market/8760
This latest report researches the industry structure, sales, revenue,…
Hypertension Management Devices Market: Rise in Prevalence of Resistant Hyperten …
Market Analysis and Insights of Hypertension Management Devices Market
Hypertension Management Devices Market to account USD 9.50 billion and growing at a CAGR of 7.27% by 2032. Although there are still numerous variations available, the major market players are currently developing and testing clinical versions of hypertension treatment devices. Due to the lack of available effective medications, these medical devices are being created with the primary goal of managing cardiovascular illnesses…
Anti-hypertension - Drug Pipeline Landscape, 2022
Hypertension also known as high blood pressure is a condition where the force of blood pushing against the arterial walls of heart is consistently higher than the normal. Hypertension can be identified as primary/essential (without a known cause such as age, genetics, sedentary lifestyle, alcohol consumption, high sodium intake etc.) and secondary (due to an underlying condition as its cause such as congenital heart defects, kidney diseases, endocrinal issues, side…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
Renal Hypertension: Diagnosis & Treatment
“Hypertension & Cardiovascular disease after Kidney Transplantation” is one of the workshops to be conducted by Dr. Hossein Tabriziani of Loma Linda University, USA under the session ‘Renal Hypertension’ at the meeting 2nd International Conference on Hypertension & Healthcare which is going to be held at Amsterdam, Netherlands during September 11-13, 2017.
High blood pressure is a leading cause of kidney disease and kidney failure ESRD (end stage renal disease). Hypertension…
